Abbott Laboratories Powers U.S. Home Diagnostics Advance as Market Scales from USD 7.6 Billion in 2025 to USD 14.6 Billion by 2036 at 6.1% CAGR

ROCKVILLE, MD /August 3, 2026 - The global home diagnostics market was valued at USD 7.6 billion in 2025. It is projected to reach USD 8.1 billion (also stated as USD 8.06 billion) in 2026 and USD 14.6 billion (also stated as USD 14.58 billion) by 2036, expanding at a CAGR of 6.1% and creating an absolute dollar opportunity of USD 6.52 billion between 2026 and 2036.

Glucose Monitoring is anticipated to account for 46.0% (also stated as 46%) of the product segment in 2026, while Pharmacies is expected to remain the leading application/distribution channel with around 48.0% share.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=1892

Key Findings

Market valued at approximately USD 7.6 billion in 2025.
2026 estimate: USD 8.1 billion / USD 8.06 billion.
2036 projection: USD 14.6 billion / USD 14.58 billion.
CAGR 2026-2036: 6.1%.
Absolute opportunity 2026-2036: USD 6.52 billion.
Glucose Monitoring product share 2026: 46%.
Lateral Flow technology share 2026: 52%.
Pharmacies share: around 48%.
Fastest country growth: USA at 7%, Mexico at 6.6%.
Note: The source report lists both rounded (USD 8.1 billion / USD 14.6 billion) and more precise (USD 8.06 billion / USD 14.58 billion) figures for 2026 and 2036 values. It also states Asia Pacific as the fastest-growing region while identifying USA (7%) and Mexico (6.6%) as the key growth markets.

Growth Drivers

Rising chronic disease prevalence, particularly diabetes, expands the consumer base for at-home monitoring devices and test strips.
Growing consumer health awareness and preference for proactive health management drive adoption of rapid diagnostic tests for infectious diseases and wellness markers.
Expansion of pharmacy and e-commerce distribution channels improves access in underserved regions.
Technological advances in lateral flow, biosensor, and connected device platforms improve test accuracy and user experience for non-clinical users.
Increasing telehealth adoption creates demand for home diagnostic data that integrates with remote clinical consultation workflows.
Rising disease prevalence and aging populations expand the addressable patient population.
Increasing institutional adoption and clinical guideline integration support procurement growth.
Expanding healthcare infrastructure in developing economies creates new procurement demand.

Segment Analysis

By Product

Glucose Monitoring holds approximately 46% of the product segment in 2026, reflecting sustained demand from primary use cases, established procurement patterns, and broad applicability.
Other product categories include Pregnancy Fertility (pregnancy test kits, ovulation prediction kits, fertility monitoring devices) and Others (infectious disease test kits, cardiac marker test kits, cholesterol test kits).
Connected diagnostic devices with smartphone integration and telehealth linkage are emerging as the fastest-growing product category, shifting users from standalone kits toward devices that transmit results, enable trend tracking, and support remote consultation, particularly for chronic disease management.

By Technology

Lateral Flow is expected to account for approximately 52% of the technology segment in 2026, shaped by institutional procurement requirements, clinical adoption patterns, and established end-use applications.
Remaining technology segments include Biosensors (electrochemical, optical, wearable) and Others (microfluidic technology, digital diagnostic platforms, lab-on-chip systems).

By Distribution / Application and Deployment

Distribution segments: Pharmacies (hospital, independent, chain), Online (e-commerce platforms, brand-owned websites, third-party marketplaces), Retail (supermarkets/hypermarkets, convenience stores, health and wellness stores).
Pharmacies lead with around 48% share.
Deployment: Reusable Devices (long-term, monitoring, connected) and Disposable Kits (single-use, rapid test, self-test).

Country-Level Growth Comparison

Country

CAGR (%)

One-line commercial condition

USA

7%

Expanding healthcare infrastructure and rising institutional investment

Mexico

6.6%

Government healthcare programs and increasing clinical adoption

Germany

6.3%

Expanding healthcare infrastructure and rising institutional investment

France

6.2%

Expanding healthcare infrastructure and rising institutional investment

UK

6%

Expanding healthcare infrastructure and rising institutional investment

South Korea

5.9%

Mature market with steady growth from established systems and replacement demand

Japan

5.7%

Mature market with steady growth from established systems and replacement demand

Source: Fact.MR analysis. North America maintains a leading position; Europe shows steady demand driven by regulatory frameworks, clinical standards, and aging demographics.

Competitive Landscape

Abbott Laboratories, Roche Holding AG, and Siemens Healthineers hold strong positions through broad portfolios and established distribution networks.
QuidelOrtho Corporation, Becton, Dickinson and Company, and Bio-Rad Laboratories compete across specific segments, price tiers, and regional markets.
Additional companies with established or focused positions: ACON Laboratories, Inc., iHealth, Inc., Everlywell Inc., Cue Health Inc.
The landscape is moderately fragmented. Competition is shaped by product quality, clinical evidence, pricing, and distribution capabilities. Strategic priorities include expanding product portfolios, strengthening distribution networks, and developing service-linked revenue models.

Recent Developments

Abbott Laboratories - Product Portfolio Expansion (January 2026): expanded its product portfolio targeting growing demand segments.
Roche Holding AG - Market Expansion (2025): broadened geographic presence through distribution partnerships.
Siemens Healthineers - Technology Enhancement (2025): introduced technology improvements targeting performance and compliance.

Restraints

Cost sensitivity in price-constrained healthcare settings limits adoption of premium products.
Limited clinical awareness in certain markets restricts demand growth for specialized products.
Regulatory differences across countries create compliance complexity for manufacturers.

How to Choose: Buyer Decision Guide for Procurement and R&D Teams

Prioritize product performance and clinical evidence alignment with institutional or consumer use cases, as these factors shape purchasing decisions alongside pricing and distribution capabilities.
Evaluate technology fit, particularly Lateral Flow (52% share in 2026) for established rapid testing versus Biosensors or connected platforms for continuous monitoring and telehealth integration.
Assess distribution channel access, noting Pharmacies' around 48% share and the role of online and retail channels in expanding reach.
Consider deployment model (reusable/connected devices versus disposable kits) based on need for recurring engagement versus one-time use, especially for chronic disease management.
Review regulatory compliance complexity across target countries, given differences that affect manufacturers.
Examine portfolio breadth and recent expansions (for example, Abbott's January 2026 portfolio moves or Roche's 2025 distribution partnerships) for coverage of glucose monitoring, infectious disease, and wellness testing.

Unlock 360° insights for strategic decision making and investment planning: https://www.factmr.com/report/1892/home-diagnostics-market

Report Scope and Availability

The report covers the global home diagnostics market for consumer-accessible diagnostic devices and test kits used outside clinical settings, segmented by product (Glucose Monitoring, Pregnancy Fertility, Others), distribution (Pharmacies, Online, Retail), technology (Lateral Flow, Biosensors, Others), deployment (Reusable Devices, Disposable Kits), and region (North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa), with forecasts for 2026 to 2036. It includes 170 pages, 40 tables, and 117 figures. Quantitative units reference the USD 8.06 billion to USD 14.58 billion range at 6.1% CAGR.

Explore More Related Studies Published by Fact.MR Research

Breast Cancer Diagnostics Market- https://www.factmr.com/report/55/breast-cancer-diagnostics-market

Viral Antigens Market- https://www.factmr.com/report/1305/viral-antigens-market

Vestibular Testing Systems Market- https://www.factmr.com/report/1313/vestibular-testing-market

Canine Separation Anxiety Treatment Market- https://www.factmr.com/report/1490/canine-separation-anxiety-treatment-market

Dental Consumables Market- https://www.factmr.com/report/4420/dental-consumables-market

Flag: The quote attributed to analyst S.N. Jha is sourced directly from published commentary on the report page and requires standard PR media sign-off before official press wire dissemination.

- Contact Us -
11140 Rockville Pike, Suite 400, Rockville,
MD 20852, United States
Tel: +1 (628) 251-1583 | sales@factmr.com

About Fact.MR

Fact.MR is a global market research and consulting firm, trusted by Fortune 500 companies and emerging businesses for reliable insights and strategic intelligence. With a presence across the U.S., UK, India, and Dubai, we deliver data-driven research and tailored consulting solutions across 30+ industries and 1,000+ markets. Backed by deep expertise and advanced analytics, Fact.MR helps organizations uncover opportunities, reduce risks, and make informed decisions for sustainable growth.

This release was published on openPR.